姑息性放疗对头颈癌患者健康相关生活质量的影响——一项多中心前瞻性队列研究结果
这项多中心前瞻性观察研究纳入21例需姑息性放疗(EQD2Gy<60 Gy)的头颈癌患者,以放疗开始后8周为主要随访点,采用EORTC QLQ-C30、QLQ-H&N43及NRS疼痛评估患者报告结局。 predefined领域均值未达10分的最小重要差异,但8周时有数据者中71%(5/7)主要症状领域和40%(2/5)次要症状领域达到MID,NRS疼痛显著改善(p=0.041)。
要点
- 8周时有数据者中71%(5/7)主要症状领域和40%(2/5)次要症状领域达到10分MID。
- NRS疼痛在8周时有数据者中显著改善(Wilcoxon符号秩检验p=0.041)。
- ≥3级急性黏膜炎(CTCAE v5.0)发生率为44%(8/18),中位总生存11个月。
核心结论
- 尽管患者数量少且存在选择偏倚风险,本研究通过患者报告结局显示姑息性放疗对头颈癌有一定获益证据。
研究设计与样本
- 多中心前瞻性观察研究,纳入头颈癌且指示姑息性放疗(EQD2Gy<60 Gy)的患者。
- 2020年6月至2022年6月筛查61例,纳入21例;放疗第一分次时有健康相关生活质量数据18例,8周时有8例。
- 主要随访时间为放疗后8周(t8w),患者报告结局工具包括EORTC QLQ-C30、EORTC QLQ-H&N43及NRS疼痛。
主要发现
- 从第一分次至8周,predefined领域均值未达到10分的最小重要差异(MID)。
- 8周时有健康相关生活质量数据的患者中,主要症状领域71%(5/7)达到MID,次要症状领域40%(2/5)达到MID。
- 8周时有数据者NRS疼痛经Wilcoxon符号秩检验显著改善(p=0.041)。
- ≥3级急性黏膜炎(CTCAE v5.0)发生率为44%(8/18)。
- 中位总生存为11个月。
关键数值与推荐
- 姑息性放疗指征为EQD2Gy<60 Gy。
- 最小重要差异(MID)定义为10分。
- 按方案详细报告5个患者报告结局领域,以及对应于个体患者主要和次要症状的患者报告结局领域。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者数量少。
- 存在选择偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Palliative radiotherapy for patients with head and neck cancer can be used to alleviate symptoms. Only a few studies have investigated its impact on patient-reported outcomes (PRO). Therefore, we conducted a prospective multicenter observational study. The primary objective was to assess changes in health-related quality of life (HrQoL) per PRO. METHODS: Eligibility criteria included i.) head and neck cancer and ii.) palliative radiotherapy indicated (EQD2Gy < 60 Gy). The primary follow-up date was eight weeks after radiotherapy (t8w). PRO measures included the EORTC QLQ-C30 and EORTC QLQ-H&N43 and pain per Numeric Rating Scale (NRS). Per protocol, five PRO domains were to be reported in detail as well as PRO domains corresponding to a primary and secondary symptom as determined by the individual patient. We defined a minimal important difference (MID) of 10 points. RESULTS: From 06/2020 to 06/2022, 61 patients were screened and 21 patients were included. Due to death or decline in health-status, HrQoL data was available for 18 patients at the first fraction and for eight patients at t8w. The MID was not met for the predefined domains in terms of mean values as compared from first fraction to t8w. Individually in those patients with available HrQoL data at t8w, 71% (5/7) improved in their primary and 40% (2/5) in their secondary symptom domain reaching the MID from first fraction to t8w, respectively. There was a significant improvement in pain per NRS in those patients with available data at t8w per Wilcoxon signed rank test (p = 0.041). Acute mucositis of grade ≥3 per CTCAE v5.0 occurred in 44% (8/18) of the patients. The median overall survival was 11 months. CONCLUSION: Despite low patient numbers and risk of selection bias, our study shows some evidence of a benefit from palliative radiotherapy for head and neck cancer as measured by PRO.German Clinical Trial Registry identifier: DRKS00021197.
引用
- Weiss ML, Domschikowski J, Krug D, et al. The impact of palliative radiotherapy on health-related quality of life in patients with head and neck cancer - Results of a multicenter prospective cohort study. Clin Transl Radiat Oncol. 2023. PMID: 37206410. doi:10.1016/j.ctro.2023.100633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。